ASLAN Pharmaceuticals Limited (ASLN)
Market Cap | 44.63M |
Revenue (ttm) | n/a |
Net Income (ttm) | -51.38M |
Shares Out | 16.35M |
EPS (ttm) | -3.75 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,568 |
Open | 2.73 |
Previous Close | 2.64 |
Day's Range | 2.73 - 2.73 |
52-Week Range | 1.71 - 4.95 |
Beta | 1.86 |
Analysts | Buy |
Price Target | 19.13 (+600.73%) |
Earnings Date | Apr 26, 2023 |
About ASLN
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop im... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ASLN stock is "Buy." The 12-month stock price forecast is $19.13, which is an increase of 600.73% from the latest price.
News

ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
SAN MATEO, Calif. and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatment...

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
SAN MATEO, Calif. and SINGAPORE, March 24, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatment...

ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting
SAN MATEO, Calif. and SINGAPORE, March 14, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatment...

ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
SAN MATEO, Calif. and SINGAPORE, March 10, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative ...

Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. (ASLN), Here's Why It's a 'Buy' Now
ASLAN Pharmaceuticals Ltd. (ASLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.

Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Aspira (AWH) have performed compared to their sector so far this year.

ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata
SAN MATEO, Calif. and SINGAPORE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments...

ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M
SAN MATEO, Calif. and SINGAPORE, Feb. 24, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative t...

ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients
SAN MATEO, Calif. and SINGAPORE, Feb. 24, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative t...

ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
SAN MATEO, Calif. and SINGAPORE, Dec. 16, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments...

ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference
SAN MATEO, Calif. and SINGAPORE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments...

ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
SAN MATEO, Calif. and SINGAPORE, Oct. 28, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments...

ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
MENLO PARK, Calif. and SINGAPORE, Sept. 14, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...

ASLAN Pharmaceuticals Announces Acceptance of Two Late-Breaking Abstracts for e-Poster Presentation at the 51st Annual European Society for Dermatological Research Meeting
MENLO PARK, Calif. and SINGAPORE, Sept. 13, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatmen...

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Multiple Posters at the 31st Annual European Academy of Dermatology and Venereology (EADV) Congress
MENLO PARK, Calif. and SINGAPORE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatmen...

ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
MENLO PARK, Calif. and SINGAPORE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatment...

ASLAN PHARMACEUTICALS SIGNS LICENSE AGREEMENT WITH BELLE.AI TO USE BELLESTUDY™ IMAGE CAPTURE SOFTWARE IN ATOPIC DERMATITIS CLINICAL TRIALS
MENLO PARK, Calif. and SINGAPORE and CAMBRIDGE, Mass.

ASLAN Pharmaceuticals Signs License Agreement With Belle.ai to Use belleStudy™ Image Capture Software in Atopic Dermatitis Clinical Trials
MENLO PARK, Calif. and CAMBRIDGE, Mass. and SINGAPORE, Aug. 25, 2022 (GLOBE NEWSWIRE) -- BelleTorus Corporation (“Belle.ai”) and ASLAN Pharmaceuticals (Nasdaq: ASLN), today announced that ASLAN has li...

ASLAN Pharmaceuticals to Host a Hybrid R&D Day on September 15, 2022
MENLO PARK, Calif. and SINGAPORE, Aug. 22, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatment...

ASLAN Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- Company maintains healthy operating position with US$78.1 million in cash, cash equivalents and short-term investments as of June 30, 2022, runway through late 2023- Three abstracts showcasing new ...

ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis
MENLO PARK, Calif. and SINGAPORE, June 07, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatment...

ASLAN Pharmaceuticals to Participate in Fireside Chat at Jefferies Global Healthcare Conference
MENLO PARK, Calif. and SINGAPORE, May 31, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments ...

ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting
MENLO PARK, Calif. and SINGAPORE, May 20, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments...

ASLAN Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
MENLO PARK, Calif. and SINGAPORE, April 27, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatmen...

ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022
MENLO PARK, Calif. and SINGAPORE, April 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatment...